Replies to post #226521 on Avid Bioservices Inc (CDMO)

[itsabouttime]

This is a good read out. Thought provoking. This one is not throw away material for the dumster. Pardon the pun. GJ

[Protector]

dubster, your perception remark is correct.

Now, this being said, in the case of PPHM it is fed by an exceptional situation.

If you look other biotech/Pharm's small/mid/large thenyou see more products because they have more 'condition targeted' product. A poduct for X, one for Y another for Z, etc. As a consequence one thinks, wow, they have a lot in the pipeline.

With PPHM actually the platform is the pipeline Bavituximab. The other Cotara is temporarily or according others permanently, shelfed.

But Bavituximab is not a product for a single condition. You need only that in the pipeline and if you prove once that it works well in say SUNRISE you can then start to work towards it's use in an impressive list of cancers, viral, inflammation, digital imaging and other area's.

So actually, Bavituximab is like having 50 pipelines. That is what will make the leverage huge.